In view of its aberrant expression in carcinomas and especially in urothelial bladder cancer [6], its role in cell motility, invasion, angiogenesis, and resistance to apoptosis, N-cadherin is a prime target for anti-tumor therapies. Here, CDH2 is linked to bladder transitional cell carcinoma.